Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Actreen luer lock catheter male Tiemann tip 8Ch-16Ch
21020001067
|
Actreen luer lock catheter male Tiemann tip 8Ch-16Ch | Catheters | Appliances | No data available |
|
Actreen set catheter female 6Ch-16Ch
21020001076
|
Actreen set catheter female 6Ch-16Ch | Catheters | Appliances | No data available |
|
Actreen set catheter male 8Ch-18Ch
21020001075
|
Actreen set catheter male 8Ch-18Ch | Catheters | Appliances | No data available |
|
Actreen set catheter male Tiemann tip 8Ch-16Ch
21020001077
|
Actreen set catheter male Tiemann tip 8Ch-16Ch | Catheters | Appliances | No data available |
|
AcuBond strips
20050200305
|
AcuBond strips | Tracheostomy & Laryngectomy Appliances | Dressings | No data available |
|
Acumor XL 8mg capsules
0411000F0BEAAAE
|
Acumor XL | Galantamine | Central Nervous System | No data available |
|
Acupan 20mg/1ml solution for injection ampoules
0407010P0BBABAA
|
Acupan | Nefopam hydrochloride | Central Nervous System | No data available |
|
Acupan 30mg tablets
0407010P0BBAAAB
|
Acupan | Nefopam hydrochloride | Central Nervous System | No data available |
|
AcuSal 1.17g/5ml (4mmol/ml) oral solution
0902012L0BGACDG
|
AcuSal | Sodium chloride | Nutrition and Blood | No data available |
|
AcuSal 1.46g/5ml (5mmol/ml) oral solution
0902012L0BGABDH
|
AcuSal | Sodium chloride | Nutrition and Blood | No data available |
|
AcuSal 292.5mg/5ml (1mmol/ml) oral solution
0902012L0BGAADD
|
AcuSal | Sodium chloride | Nutrition and Blood | No data available |
|
ACWY Vax vacc inj 0.5ml vials
1404000X0BEAAAC
|
ACWY Vax | Meningococcal A + C + W135 + Y vaccine | Immunological Products and Vaccines | No data available |
|
Adalimumab 20mg/0.2ml inj pre-filled syringes
1001030S0AAAFAF
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 20mg/0.4ml inj pre-filled syringes
1001030S0AAAIAI
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml inj pre-filled syringes
1001030S0AAAAAA
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 40mg/0.8ml solution for injection vials
1001030S0AAACAC
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled disposable devices
1001030S0AAAHAH
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adalimumab 80mg/0.8ml inj pre-filled syringes
1001030S0AAAGAG
|
Adalimumab | Adalimumab | Musculoskeletal and Joint Diseases | No data available |
|
Adcortyl in Orabase 0.1% oromucosal paste
1203010T0BBAAAG
|
Adcortyl in Orabase | Triamcinolone acetonide | Ear, Nose and Oropharynx | No data available |
|
Adcortyl In Orabase for Mouth Ulcer 0.1% oromucosal paste
1203010T0BBABAG
|
Adcortyl in Orabase | Triamcinolone acetonide | Ear, Nose and Oropharynx | No data available |
|
Add Ins low protein sachets and tablets
090401000BBNEA0
|
Proprietary compound foods for special diets | Other food for special diet preparations | Nutrition and Blood | No data available |
|
Add Ins oral powder 18.2g sachets
090401000BBNKA0
|
Proprietary compound foods for special diets | Other food for special diet preparations | Nutrition and Blood | No data available |
|
Addaven concentrate for solution for infusion 10ml ampoules
0903000R0BBAAAA
|
Addaven | Addaven (Generic) | Nutrition and Blood | No data available |
|
Adderall 10mg tablets
0404000L0BFAAAV
|
Adderall | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Adderall XR 10mg capsules
0404000L0BFAFBH
|
Adderall | Dexamfetamine sulfate | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.